JP2014502252A - 作用持続時間が増した改変ポリペプチド - Google Patents

作用持続時間が増した改変ポリペプチド Download PDF

Info

Publication number
JP2014502252A
JP2014502252A JP2013531789A JP2013531789A JP2014502252A JP 2014502252 A JP2014502252 A JP 2014502252A JP 2013531789 A JP2013531789 A JP 2013531789A JP 2013531789 A JP2013531789 A JP 2013531789A JP 2014502252 A JP2014502252 A JP 2014502252A
Authority
JP
Japan
Prior art keywords
seq
modified polypeptide
amino acid
acid sequence
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013531789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502252A5 (enExample
Inventor
スーミトラ・エス・ゴッシュ
メアリー・エリクソン
デイビッド・シー・リッツィンガー
ジジエン・グオ
ジョナサン・デイビッド・ロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Publication of JP2014502252A publication Critical patent/JP2014502252A/ja
Publication of JP2014502252A5 publication Critical patent/JP2014502252A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013531789A 2010-09-28 2011-09-28 作用持続時間が増した改変ポリペプチド Pending JP2014502252A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38740210P 2010-09-28 2010-09-28
US61/387,402 2010-09-28
US42209110P 2010-12-10 2010-12-10
US61/422,091 2010-12-10
PCT/US2011/053786 WO2012050930A2 (en) 2010-09-28 2011-09-28 Engineered polypeptides having enhanced duration of action

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017036849A Division JP6412183B2 (ja) 2010-09-28 2017-02-28 作用持続時間が増した改変ポリペプチド

Publications (2)

Publication Number Publication Date
JP2014502252A true JP2014502252A (ja) 2014-01-30
JP2014502252A5 JP2014502252A5 (enExample) 2014-11-13

Family

ID=45938879

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013531789A Pending JP2014502252A (ja) 2010-09-28 2011-09-28 作用持続時間が増した改変ポリペプチド
JP2013531786A Active JP6174489B2 (ja) 2010-09-28 2011-09-28 高可溶性レプチン
JP2016235165A Active JP6608799B2 (ja) 2010-09-28 2016-12-02 高可溶性レプチン
JP2017036849A Active JP6412183B2 (ja) 2010-09-28 2017-02-28 作用持続時間が増した改変ポリペプチド
JP2019193539A Pending JP2020033366A (ja) 2010-09-28 2019-10-24 高可溶性レプチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013531786A Active JP6174489B2 (ja) 2010-09-28 2011-09-28 高可溶性レプチン
JP2016235165A Active JP6608799B2 (ja) 2010-09-28 2016-12-02 高可溶性レプチン
JP2017036849A Active JP6412183B2 (ja) 2010-09-28 2017-02-28 作用持続時間が増した改変ポリペプチド
JP2019193539A Pending JP2020033366A (ja) 2010-09-28 2019-10-24 高可溶性レプチン

Country Status (14)

Country Link
US (6) US20130274182A1 (enExample)
EP (4) EP3305315A1 (enExample)
JP (5) JP2014502252A (enExample)
CN (2) CN103547590B (enExample)
BR (3) BR122021020041B1 (enExample)
CA (3) CA2813038C (enExample)
CY (2) CY1119023T1 (enExample)
DK (3) DK2621515T3 (enExample)
EA (2) EA032917B1 (enExample)
ES (3) ES2873253T3 (enExample)
MX (2) MX351128B (enExample)
PL (1) PL3241558T3 (enExample)
PT (2) PT2621519T (enExample)
WO (2) WO2012050930A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525442A (ja) * 2015-08-05 2018-09-06 シャンシー・ミコ・テクノロジー・リミテッド・カンパニー 抗凝固・抗血小板活性を有するマルチターゲット化合物及びその製法並びに用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2590993T3 (en) 2010-07-09 2015-06-29 Affibody Ab Polypeptides
BR122021020041B1 (pt) * 2010-09-28 2023-03-07 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2013148966A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
JP6590695B2 (ja) * 2012-09-25 2019-10-16 アフィボディ・アーベー アルブミン結合ポリペプチド
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3038642A4 (en) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3083675B1 (en) 2013-12-20 2018-03-07 Affibody AB Engineered albumin binding polypeptide
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
WO2016034604A1 (en) * 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
HK1248137A1 (zh) 2015-05-28 2018-10-12 阿尔莫生物科技股份有限公司 用於治疗癌症的聚乙二醇化白细胞介素-10
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
MX380314B (es) 2015-09-22 2025-03-12 Univ California Citotoxinas modificadas y su uso terapeutico.
WO2017054832A1 (en) 2015-10-02 2017-04-06 University Of Copenhagen Small molecules blocking histone reader domains
RS64850B1 (sr) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Metodi za detektovanje neutrališućih antitela na leptin
CA3049806A1 (en) * 2017-01-30 2018-08-02 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
BR112020019944A2 (pt) * 2018-04-13 2021-01-26 Massachusetts Institute Of Technology tratamentos modificados para reparo do cabelo e retenção de cor duradoura
EP3711772A1 (en) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
US20240391963A1 (en) * 2021-09-24 2024-11-28 The Uab Research Foundation Control of subunit stoichiometry in single-chain msp nanopores
WO2025240494A1 (en) * 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10513450A (ja) * 1995-01-31 1998-12-22 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
JP2007505840A (ja) * 2003-09-19 2007-03-15 ノボ　ノルディスク　アクティーゼルスカブ 新規ｇｌｐ−１誘導体
WO2009064298A1 (en) * 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2009100255A2 (en) * 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
US20100104588A1 (en) * 2002-06-28 2010-04-29 Dennis Mark S Serum albumin binding peptides for tumor targeting
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain

Family Cites Families (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
US4695463A (en) 1985-05-24 1987-09-22 Warner-Lambert Company Delivery system for active ingredients and preparation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
AU6541090A (en) 1989-10-16 1991-05-16 Amgen, Inc. Stem cell factor
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ES2118820T3 (es) 1991-04-05 1998-10-01 Univ Washington Anticuerpos monoclonales para receptores de factores de celulas pluripotentes.
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
EP0836620A1 (en) 1995-01-31 1998-04-22 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
WO1996023815A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (en) 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
WO1996031526A1 (en) 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
EP0741187A2 (en) 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
WO1996035787A1 (en) 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity
WO1996037517A1 (en) 1995-05-26 1996-11-28 Eli Lilly And Company Rhesus ob protein and dna
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
US5581005A (en) 1995-06-16 1996-12-03 The Procter & Gamble Company Method for manufacturing cobalt catalysts
CA2224867A1 (en) 1995-06-22 1997-01-09 Eli Lilly And Company Obesity protein intermediates and their preparation and use
GB2302559B (en) 1995-06-23 1998-06-03 Draftex Ind Ltd Opening arrangements and methods for closure members
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
WO1997002004A2 (en) * 1995-06-30 1997-01-23 Eli Lilly And Company Methods for treating diabetes
AU6688896A (en) 1995-08-17 1997-03-12 Amgen, Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
WO1997016550A1 (en) 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
DK0866720T3 (da) 1995-11-22 2004-06-14 Amgen Inc OB-protein til forögelse af mager kropsmasse
WO1997020933A2 (en) 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AU2246097A (en) 1996-01-25 1997-08-20 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
NZ332879A (en) 1996-06-06 2000-09-29 Smithkline Beecham Plc Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
CA2263826A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
RU2201249C2 (ru) 1996-09-20 2003-03-27 Хехст Акциенгезелльшафт Применение антагонистов лептина для лечения резистентности к инсулину при диабете ii типа
AU4582597A (en) 1996-10-11 1998-05-11 Eli Lilly And Company Therapeutic proteins
AU5654998A (en) 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
CN1195858C (zh) 1996-12-20 2005-04-06 安姆根有限公司 Ob融合蛋白组合物及方法
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
WO1998041222A1 (en) * 1997-03-20 1998-09-24 Eli Lilly And Company Obesity protein formulations
WO1998055139A1 (en) 1997-06-06 1998-12-10 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US6326468B1 (en) 1997-06-13 2001-12-04 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
AU753205B2 (en) 1998-05-29 2002-10-10 Catalysts & Chemicals Industries Co., Ltd. Method of manufacturing photoelectric cell and oxide semiconductor for photoelectric cell
WO2000009165A1 (en) 1998-08-10 2000-02-24 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
JP2002526780A (ja) 1998-10-02 2002-08-20 アムジエン・インコーポレーテツド レプチン処置に対する素因の決定方法
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
DE60044041D1 (de) 1999-01-14 2010-04-29 Amylin Pharmaceuticals Inc Exendine zur Glucagon Suppression
DE60027409T2 (de) 1999-02-12 2007-04-12 Amgen Inc., Thousand Oaks Glykosylierte leptinzusammensetzungen und zugehörige verfahren
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
EP1214351A2 (en) * 1999-09-22 2002-06-19 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US7057015B1 (en) * 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
AU1303301A (en) 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Body weight gain inhibitors
JP2001199887A (ja) 1999-11-10 2001-07-24 Takeda Chem Ind Ltd 体重増加抑制剤
US7157564B1 (en) 2000-04-06 2007-01-02 Affymetrix, Inc. Tag nucleic acids and probe arrays
WO2001079444A2 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
US6899892B2 (en) 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
WO2004039853A1 (ja) 2002-11-01 2004-05-13 Tokuyama Corporation 重合性組成物、その硬化体の製造法および光学物品
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
ATE471340T1 (de) 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
US7898623B2 (en) 2005-07-04 2011-03-01 Semiconductor Energy Laboratory Co., Ltd. Display device, electronic device and method of driving display device
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
JP2009523177A (ja) 2006-01-11 2009-06-18 ブリストル−マイヤーズ スクイブ カンパニー ヒトグルカゴン様ペプチド−１調節因子、並びに糖尿病および関連症状の治療におけるその使用
EP1996617A2 (en) 2006-03-15 2008-12-03 Novo Nordisk A/S Amylin derivatives
JP2009538824A (ja) 2006-03-31 2009-11-12 アミリン・ファーマシューティカルズ，インコーポレイテッド 精神疾患及び障害治療用アミリン及びアミリンアゴニスト
EP2636680A3 (en) 2006-05-26 2013-12-11 Amylin Pharmaceuticals, LLC Composition and methods for treatment of congestive heart failure
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CN101113175A (zh) * 2007-04-28 2008-01-30 中国科学院西北高原生物研究所 鼠兔家族瘦素蛋白及其cDNA序列
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CN104710518A (zh) * 2007-07-31 2015-06-17 阿菲博迪公司 新白蛋白结合组合物、方法及应用
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
US8598314B2 (en) * 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
ES2662501T3 (es) 2008-10-21 2018-04-06 Novo Nordisk A/S Derivados de amilina
CN102292346B (zh) 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
CA2801223C (en) * 2010-06-04 2019-12-03 Sk Chemicals Co., Ltd. Fusion protein having factor vii activity
DK2590993T3 (en) 2010-07-09 2015-06-29 Affibody Ab Polypeptides
BR122021020041B1 (pt) 2010-09-28 2023-03-07 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
JP6121330B2 (ja) 2010-09-28 2017-04-26 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続時間が増した改変ポリペプチド
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
WO2013009539A1 (en) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10513450A (ja) * 1995-01-31 1998-12-22 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
US20100104588A1 (en) * 2002-06-28 2010-04-29 Dennis Mark S Serum albumin binding peptides for tumor targeting
JP2007505840A (ja) * 2003-09-19 2007-03-15 ノボ　ノルディスク　アクティーゼルスカブ 新規ｇｌｐ−１誘導体
WO2009064298A1 (en) * 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2009100255A2 (en) * 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PHYSIOLOGY. REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, vol. 289, no. 2, JPN6015041471, 2005, pages 545 - 553, ISSN: 0003174889 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525442A (ja) * 2015-08-05 2018-09-06 シャンシー・ミコ・テクノロジー・リミテッド・カンパニー 抗凝固・抗血小板活性を有するマルチターゲット化合物及びその製法並びに用途
US11643439B2 (en) 2015-08-05 2023-05-09 Shaanxi Micot Technology Limited Company Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
DK2621519T3 (en) 2017-10-16
JP2013543497A (ja) 2013-12-05
CA2813087A1 (en) 2012-04-19
CN103403019B (zh) 2016-10-12
PL3241558T3 (pl) 2021-08-30
PT2621519T (pt) 2017-10-04
DK3241558T3 (da) 2021-04-26
BR112013007385A2 (pt) 2021-04-20
WO2012050925A3 (en) 2012-07-05
US20160083446A1 (en) 2016-03-24
US11535659B2 (en) 2022-12-27
ES2873253T3 (es) 2021-11-03
CN103547590A (zh) 2014-01-29
BR112013007388A2 (pt) 2020-10-06
EA201390474A1 (ru) 2013-07-30
CA3138758A1 (en) 2012-04-19
US20200362006A1 (en) 2020-11-19
US20130203661A1 (en) 2013-08-08
US20230115655A1 (en) 2023-04-13
EA032917B1 (ru) 2019-08-30
EP3241558A2 (en) 2017-11-08
CA2813038C (en) 2021-12-28
MX351128B (es) 2017-10-03
MX2013003472A (es) 2013-10-30
CA2813087C (en) 2020-07-21
EP3305315A1 (en) 2018-04-11
EP2621515A4 (en) 2014-07-16
BR112013007385B1 (pt) 2022-07-26
WO2012050930A2 (en) 2012-04-19
JP6608799B2 (ja) 2019-11-20
JP6412183B2 (ja) 2018-10-24
EA201390497A1 (ru) 2013-09-30
CA2813038A1 (en) 2012-04-19
EP3241558B1 (en) 2021-03-03
WO2012050930A3 (en) 2012-06-14
DK2621515T3 (en) 2017-07-17
JP2017081939A (ja) 2017-05-18
WO2012050925A2 (en) 2012-04-19
MX2013003482A (es) 2013-10-25
BR112013007388B1 (pt) 2022-01-04
EP2621519A4 (en) 2014-07-09
CN103547590B (zh) 2017-11-28
ES2641869T3 (es) 2017-11-14
US20160137709A1 (en) 2016-05-19
EP2621515B1 (en) 2017-03-29
CY1119023T1 (el) 2018-01-10
CN103403019A (zh) 2013-11-20
US20130274182A1 (en) 2013-10-17
US10087228B2 (en) 2018-10-02
CY1119498T1 (el) 2018-03-07
JP2020033366A (ja) 2020-03-05
EP2621515A2 (en) 2013-08-07
JP6174489B2 (ja) 2017-08-02
EP2621519B1 (en) 2017-06-28
EP3241558A3 (en) 2018-05-16
BR122021020041B1 (pt) 2023-03-07
MX349054B (es) 2017-07-07
EA024507B1 (ru) 2016-09-30
EP2621519A2 (en) 2013-08-07
JP2017141232A (ja) 2017-08-17
ES2630031T3 (es) 2017-08-17
PT2621515T (pt) 2017-07-12

Similar Documents

Publication Publication Date Title
JP6412183B2 (ja) 作用持続時間が増した改変ポリペプチド
EP2729160B1 (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
HK1196093A (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
HK1196093B (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
HK1188924A (en) Leptin-abd fusion polypeptides with enhanced duration of action
HK1188924B (en) Leptin-abd fusion polypeptides with enhanced duration of action
HK1188711A (en) A chimeric seal-human leptin polypeptide with increased solubility
HK1188711B (en) A chimeric seal-human leptin polypeptide with increased solubility

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160830

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170620